

## Supplement 5. ColCorona-US Poster



### **If you have recently been diagnosed with COVID-19, you may be eligible for a research study.**

**[site name]**, partnered with the Montreal Heart Institute, is investigating whether short-term treatment with a medicine called **colchicine** can prevent hospitalization, need for a ventilator, and death related to COVID-19. The idea tested is to start colchicine early in the disease process, when you are feeling relatively ok, to prevent the development of severe symptoms.

**Colchicine** is an anti-inflammatory drug that has been used for more than 2000 years to treat inflammatory conditions such as gout. We know that in COVID-19, people get severely ill partly due to the body's overly robust immune response to the virus and colchicine dampens some parts of that type of immune response.

***You must meet the following criteria:***

- Diagnosed with definite or probable COVID-19 in the last 36 hrs
- Not hospitalized
- $\geq 40$  years old

***If you participate, you will:***

- Take one pill twice a day for 3 days and then one pill daily for 27 days (even if you are feeling better)
- Participate in 2 follow-up calls
- May receive compensation up to \$50

*To participate, you do not need to leave the home. We will courier drug to your home (within xxx miles of **[site name]**).*

If you meet the criteria listed above and would like to participate, contact us!

If you are a **[site name]** patient, contact us at **[contact information]**

If you are not a **[site name]** patient or would like to call the study hotline directly, call **1-877-536-6837** (Montreal Heart Institute toll-free open 24/7)

**Call** as soon as possible, as the study is time sensitive.

You can also visit us at **COLCORONA.NET** for more information.

The Montreal Heart Institute Colcorona Study has received a grant from the COVID-19 Therapeutics Accelerator via the Bill & Melinda Gates Foundation.